Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia
Open Access
- 10 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 49 (3), 539-542
- https://doi.org/10.1007/s15010-020-01522-4
Abstract
Background SARS-CoV-2 pandemic has posed formidable public health and clinical challenges. The use of immunosuppressive agents, such as high dose corticosteroids and cytokine inhibitors (e.g., Tocilizumab) has been suggested to contrast the hyperinflammatory process involved in the pathogenesis of the severe disease, with conflicting evidence. Among the drawbacks of immunosuppressive therapy, the risk of reactivation of latent infections, including parasitic infestations, is to be considered. Case presentation We report a case of a 59-year-old Italian patient treated with high dose intravenous dexamethasone and two intravenous doses of Tocilizumab for interstitial bilateral pneumonia associated with SARS-CoV-2 infection who developed itching, abdominal pain, and an increased eosinophil count. Stool examination confirmed the presence of S. stercoralis larvae. The patient was treated with a 4-day course of Ivermectin with full recovery. Discussion We report the first case of S. stercoralis infection following an 11-day treatment with high-dose steroids and Tocilizumab for severe COVID-19. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19.Keywords
This publication has 27 references indexed in Scilit:
- Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trialThe Lancet Infectious Diseases, 2019
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)Clinical Microbiology & Infection, 2018
- Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic CountriesThe American Journal of Tropical Medicine and Hygiene, 2017
- Epidemiology of Strongyloides stercoralis in northern Italy: results of a multicentre case–control study, February 2013 to July 2014Eurosurveillance, 2016
- Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature reviewInternational Journal of Rheumatic Diseases, 2015
- Strongyloides stercoralis infectionBMJ, 2013
- Severe strongyloidiasis: a systematic review of case reportsBMC Infectious Diseases, 2013
- Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralisCurrent Opinion in Infectious Diseases, 2012
- Strongyloides stercoralis: there but not seenCurrent Opinion in Infectious Diseases, 2010
- Severe strongyloidiasis in corticosteroid-treated patientsClinical Microbiology & Infection, 2006